Clinical trial
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
NCT00365391 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00365391 |
|---|---|
| Title | Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer |
| Official title | Phase II Study of Bevacizumab Plus Erlotinib in Patients With Advanced Hepatocellular Cancer (HCC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, erlotinib hydrochloride |
| Enrollment | 27 |
| Start date | Aug 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Jun 1, 2010 |
| First posted | Aug 17, 2006 |
| Last update posted | Jul 9, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: